Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Identification of a metastasis-associated prognostic gene signature in osteosarcoma through integrated bioinformatics and functional analysis

Summary

An integrated bioinformatics and functional study identified a metastasis-associated gene signature in osteosarcoma. Four key genes, AURKB, CDC20, KIF11, and TOP2A, were strongly associated with tumor progression and metastasis. Their high expression correlated with poor overall survival and demonstrated excellent diagnostic performance. A four-gene prognostic model showed strong predictive performance. Functional experiments confirmed their oncogenic role by promoting sarcoma cell proliferation and migration.

Critical appraisal

Clinical. This study identifies a four-gene prognostic model (AURKB, CDC20, KIF11, TOP2A) that could stratify osteosarcoma patients based on their risk of metastasis and survival. The diagnostic and predictive performance of this model suggests a potential clinical impact in the medium term (3-5 years) to guide therapeutic decisions and patient monitoring. These genes could serve as prognostic biomarkers to identify high-risk patients requiring more intensive therapies.

Molecular biology. The discovery of AURKB, CDC20, KIF11, and TOP2A as key oncogenic drivers in osteosarcoma is significant. These genes are overexpressed due to promoter hypomethylation and genomic alterations, and they promote sarcoma cell proliferation and migration. Techniques used include RT-qPCR, Western blotting, and in vitro functional assays. These findings pave the way for the development of targeted therapies against these genes or their associated pathways, with clear translational implications for future clinical trials.

Bioinfo & AI. The study employed an integrated bioinformatics approach, combining Weighted Gene Co-expression Network Analysis (WGCNA) on Gene Expression Omnibus (GEO) datasets to identify metastasis-associated gene modules. Expression, methylation, mutation, immune infiltration, and drug sensitivity analyses were performed using public databases such as TCGA, GSCA, UALCAN, and cBioPortal. The prognostic model was developed using the TARGET cohort and validated in an independent GEO dataset, demonstrating computational robustness. This approach could be clinically deployed to refine patient risk stratification.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology